Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4(+) T cells. Vaccination with such CD4(+) immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4(+) T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient's tumour with vaccines produced 'just in time'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4+ T-cell responses [36].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutated epitopes of Pbk and Actn4 were recognized and reacted to by CD8+ or CD4+ T cells, respectively, upon RNA monotope vaccinations and showed good MHC class I binding scores (‘low score’ 0.1 and 0.2, respectively) (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Additional neoatigens formulated in the mRNA vaccine may help improve the anti-tumor response of mRNA vaccines using neoantigens, such as demonstrated by Kreiter et al. (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
In the citing paper
“Interestingly, we also observed an elevated percentage of ChAT–GFP+ cells among CD4+ T cells carrying natural TCRs (TCR Vβ5–) (Fig. 4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’35.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Cited by
Items 801–900 of 1,001
Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice.
Do-Thi, V. A., Jeon, H.-M., Park, S. M., Lee, H., & Kim, Y. S. (2019) · PubMed Central · doi:10.14348/molcells.2019.0188 · Cited by 19
“S1), which is consistent with a previous report (Kreiter et al., 2015).”
Stifter, K., Dekhtiarenko, I., Krieger, J., Tissot, A. C., Seufferlein, T. T. W., Wagner, M., & Schirmbeck, R. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.04.003 · Cited by 13
HLA Class II Specificity Assessed by High-Density Peptide Microarray Interactions
Østerbye, T., Nielsen, M., Dudek, N. L., Ramarathinam, S. H., Purcell, A. W., Schafer‐Nielsen, C., & Buus, S. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000224 · Cited by 14
Juanes‐Velasco, P., Landeira‐Viñuela, A., Acebes-Fernández, V., Hernández, Á., García‐Vaquero, M. L., Arias‐Hidalgo, C., Bareke, H., Montalvillo, E., Góngora, R., & Fuentes, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642583 · Cited by 16
Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy
Wu, Y., & Feng, L. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2168640 · Cited by 13
Future prospects for cancer immunotherapy - Strategies for ineffective cancers
Wada, S., Kobayashi, S., & Tsunoda, T. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2031699 · Cited by 15
HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell Carcinoma
Miura, Y., Anami, T., Yatsuda, J., Motoshima, T., Oka, S., Suyama, K., Inoshita, N., Kinowaki, K., Urakami, S., Kamba, T., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15065 · Cited by 12
Lu, S., Hansen, M. J., Hemsath, J. R., Parrett, B. J., Zell, B. N., & Barry, M. A. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.197 · Cited by 12
“…were stimulated with an MHC I H-2K b -restricted ovalbumin (OVA) peptide as a negative control, with H-2K b -restricted adenovirus E1A peptide, with a H-2K b -restricted melanoma TRP-2 peptide, or with a truncated MHC-II-restricted B16-M30 Kif18b peptide, 36 and then an IFN-c ELISpot was performed.”
Wang, C., Chen, J., Li, J., Xu, Z., Huang, L., Zhao, Q., Chen, L., Liang, X., Hu, H., Li, G., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci172092 · Cited by 12
“Vaccination with CD4 + immunogenic neoepitopes induces cytotoxic T lymphocyte responses and confers antitumor activity in both mice and humans, highlighting the participation of CD4 + T cells in immunotherapy (4, 5).”
An Insight into Immunological Therapeutic Approach against Cancer: Potential Anti-cancer Vaccines
Kohli, A. S., Sanyal, S., Kaushal, R. S., & Dwivedi, M. (2024) · Current Genomics · doi:10.2174/0113892029319505240821063238 · Cited by 13
Zhou, J., Liu, Y., Xu, W., Bhatta, R., Han, J., Baskaran, D., Devmal, S., Leal, C., & Wang, H. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.08.005 · Cited by 13
Pati, S. S., Dhal, S., Pattnaik, R., Tripathy, S., & Kumar, S. (2025) · Current Medical Science · doi:10.1007/s11596-025-00112-5 · Cited by 14
“Because mRNA therapeutic vaccines have the potential to alter treatment results via immune responses, further research on these vaccines is needed [40].”
The Optimization of Bioorthogonal Epitope Ligation within MHC-I Complexes
Pawlak, J. B., Hos, B. J., van de Graaff, M. J., Megantari, O. A., Meeuwenoord, N. J., Overkleeft, H. S., Filippov, D. V., OSSENDORP, F. A., & van Kasteren, S. I. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00498 · Cited by 19
Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients
Balan, S., Finnigan, J. P., & Bhardwaj, N. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000251 · Cited by 13
“Some of the studies with neoantigen-based immunotherapy show a CD4 T-cell–mediated bias rather than CD8 T cells.(50) A strong CD8-mediated immune response may be critical for eliminating the tumor.”
InfluentialClinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go
Barroso‐Sousa, R., & Tolaney, S. M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00756-6 · Cited by 12
Zheng, X., Sun, Y., Li, Y., Ma, J., Lv, Y., Hu, Y., Zhou, Y., & Zhang, J. (2022) · Cells · doi:10.3390/cells12010035 · Cited by 12
“MHC class II may play a key role in tumor immune surveillance because it can bind a higher diversity of peptides than MHC class I and increase the likelihood of tumor neoantigens being recognized by CD4+ T cells [55,56].”
BackgroundMillar, D. G., Yang, S. Y. C., Sayad, A., Zhao, Q., Nguyen, L. T., Warner, K., Sangster, A. G., Nakatsugawa, M., Murata, K., Wang, B. X., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03413-7 · Cited by 13
mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma
Tusup, M., Läuchli, S., Jarzębska, N. T., French, L. E., Chang, Y., Eisenring, M., Su, A. A. H., Kündig, T. M., Guenova, E., & Pascolo, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071040 · Cited by 13
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms
Nowroozi, A. A., Khalili, N., Razi, S., Keshavarz‐Fathi, M., & Rezaei, N. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2072206 · Cited by 14
Wang, R., Yang, Y., Ye, W.-W., Xiang, J., Chen, S., Zou, W., Wang, X., Chen, T., & Cao, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.588080 · Cited by 16
“Somatic mutations presented in cancer genome lead to the creation of neo-antigens, which serve as the target for anti-tumor immune activity (13, 14).”
BackgroundJoshi, K., Chain, B., Peggs, K. S., & Quezada, S. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027086 · Cited by 14
“The importance of MHC class II presented neoantigens and tumor-reactive CD4þ cells has also been reported (Kreiter et al. 2015).”
BackgroundAkhavan, D., Subham, S., Jeppson, J. D., Aguilar, B., Wong, R. A., Hibbard, J. C., Hui, S. K., Wong, J. Y. C., Forman, S. J., Alizadeh, D., et al. (2024) · Cells · doi:10.3390/cells13131075 · Cited by 11
“Our observation of increased MHC-II expression in the TME after SRS or SRS plus mCAR T, which is also supported in other murine solid tumor models, where a larger portion of the immunogenic mutanome is presented by MHC-II rather than MHC-I, resulting in recognition by CD4 T cells [41].”
BackgroundOstroumov, D., Benne, N., Vigario, F. L., Escalona-Rayo, O., Dodz, K., Sauer, S., Suhl, L., Wedemeyer, H. H., Kühnel, F., Slütter, B., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01249-4 · Cited by 12
“On day 10 after tumor implantation, there were no detectable immune responses in the untreated control group or the group receiving checkpoint inhibition, whereas low frequencies of Adpgk mut -speci fi c CD8 + T cells were detected in the groups that received LS priming (Fig.”
Abbar, B., Labrèche, K., Cadranel, J. L., Veyri, M., Morin, V., Thiam, F. S., Désiré, N., Baron, M., Guillerm, E., Perrier, A., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.02.001 · Cited by 11
Current Understanding Regarding the Glioma Microenvironment and Impact of the Immune System
Demir, E., Montgomery, D., Saloum, A., Yaghi, N. K., & Karsy, M. J. (2025) · Neuroglia · doi:10.3390/neuroglia6010013 · Cited by 11
“…are generally viewed as safe, but the induction of an efficacious antitumor immunity may be hampered by the fact that many of these self-antigens are expressed in the thymus, resulting in central T cell tolerance and the development of antigen-specific suppressive T-regulatory cells [53,54].”
Garde, C., Pavlidis, M. A., Garces, P., Lange, E. J., Ramarathinam, S. H., Sokač, M., Pandey, K., Faridi, P., Ahrenfeldt, J., Chung, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01107-y · Cited by 12
“AH1 has been shown to drive strong CD8 + T-cell responses and to confer protection in the CT26 model 19 – 21, 23 , but optimal ef fi cacy ObsERV_B16F10 vaccination led to signi fi cant tumor growth delay and vaccine-speci fi c immune responses of comparable magnitude to the TAA_NeoAgs_B16F10 pool…”
Unraveling the Role of the Microbiota in Cancer Immunotherapy: A New Frontier
Wang, S., Li, S., Zhang, M., Liu, R., Ye, X., Mao, S., Yu, J., Xie, X., & Tan, W. (2025) · Research · doi:10.34133/research.0744 · Cited by 13
Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy
Peng, Y., Zhan, L., Shi, J., Wang, J., Li, Y., Sun, X., Lv, J., Yang, H., Qiu, Z., Liu, X., et al. (2025) · MedComm · doi:10.1002/mco2.70321 · Cited by 15
Unmasking targets of antitumor immunity via high-throughput antigen profiling
Battaglia, S., & Muhitch, J. B. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.03.001 · Cited by 12
Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities
Rezaei, M., Danilova, N. D., Soltani, M., Savvateeva, L. V., Tarasov, V. V., Ganjalıkhani-Hakemi, M., Bazhin, A. V., & Zamyatnin, A. A. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220214103533 · Cited by 12
Circular RNAs as a potential source of neoepitopes in cancer
Xia, J., Li, S., Ren, B., & Zhang, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098523 · Cited by 11
“This higher prevalence of HLA class-II neoepitopes compared to class-I neoepitopes is consistent with the findings of previous studies and also with the greater flexibility of peptide binding in the groove of HLA class-II (46) (Supplementary Figure 2B).”
ResultTumor-reactive T helper cells in the context of vaccination against glioma
Zhao, B., Kilian, M., Bunse, T., Platten, M., & Bunse, L. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.013 · Cited by 12
Santry, L. A., van Vloten, J. P., AuYeung, A. W. K., Mould, R. C., Yates, J. G. E., McAusland, T. M., Petrik, J., Major, P. P., Bridle, B. W., & Wootton, S. K. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1325558 · Cited by 12
“Some reports suggest a crucial role for Tconv in tumor clearance (Perez-Diez et al., 2007; Kreiter et al., 2015), while others propose that they are dispensable (Zamarin et al., 2017), which might be due to their ability to aide in robust 10.3389 /fmicb.2024.1325558 Frontiers in Microbiology 17…”
BackgroundInfluentialWang, B., Liu, Y., Xiong, F., & Wang, C. (2024) · Pharmaceuticals · doi:10.3390/ph17060678 · Cited by 14
“Considering the tendency of tumor cells to reduce the expression of MHC I, thereby evading the killing effect of cytotoxic T lymphocytes (CTLs), the traditional killing of tumors by CD8 + T cells often fails to achieve the expected outcome [23,43,44].”
BackgroundPan, W., Wang, Y., Tian, S., Ma, X., & Min, Y. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202405773 · Cited by 11
Recent developments in neoantigen-based cancer vaccines
Hodge, K. G., Supabphol, S., Kumar, P., Poomipak, W., & Pisitkun, T. (2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-120520-0841 · Cited by 15
Neoantigen Discovery in Human Cancers
Mardis, E. R. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000248 · Cited by 11
“RNAseq data also characterize the expression level of the mutated allele relative to the unmutated (wild-type) allele and provide a critical component of class II neoantigen prediction.(14) As mentioned previously, fusion proteins that result from novel juxtaposition of exons from different genes, due to inversion, tr…”
Kosaka, A., Yajima, Y., Hatayama, M., Ikuta, K., Sasaki, T., Hirai, N., Yasuda, S., Nagata, M., Hayashi, R., Harabuchi, S., et al. (2021) · Cancer Science · doi:10.1111/cas.14973 · Cited by 12
Jain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_20 · Cited by 13
Personalized Neoantigen DNA Cancer Vaccines: Current Status and Future Perspectives
Viborg, N., Kleine‐Kohlbrecher, D., & Rønø, B. (2024) · Journal of Cellular Immunology · doi:10.33696/immunology.6.188 · Cited by 10
de Graaf, J. F., Pesic, T., Spitzer, F. S., Oosterhuis, K., Camps, M. G. M., Zoutendijk, I., Teunisse, B., Zhu, W., Arakelian, T., Zondag, G. C. M., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200835 · Cited by 14
“16 What ’ s more, clinical studies indicated that neoantigen-speci fi c CD4 + T cells can be essential for the success of tumor-in fi l-trating lymphocyte therapy.”
Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics
Velz, J., Freudenmann, L. K., Medici, G., Dubbelaar, M. L., Mohme, M., Ghasemi, D. R., Scheid, J., Kowalewski, D. J., Patterson, A. B., Zeitlberger, A. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56268-0 · Cited by 10
“The importance of mapping not only HLA class I peptides but also the HLA class II pep-tidome is based on data on the crucial role of HLA class II antigens and CD4+ helper T cells in clinical anti-tumor responses 42 – 44 .”
Li, C., Ke, F., Mao, S., Montemayor, Z., Traore, M. D. M., Balsa, A., Djibo, M., Karekar, N., Hu, H., Wen, H., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c15113 · Cited by 10
Xiao, L., Duan, R., Liu, W., Zhang, C., Ma, X., Xian, M., Wang, Q., Guo, Q., Xiong, W., Pan, S., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00935-0 · Cited by 12
“Moreover, CD4 + T cells can specifically recognize tumor neoantigens and secrete IFNγ against mutant tumors 18,51 .”
InfluentialDNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets
Bhojnagarwala, P. S., Jose, J. S., Zhao, S., & Weiner, D. B. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.008 · Cited by 10
“148,149 Very recently, four high-profile studies described clinical trial results from the use of nucleic acid vaccines targeting neoantigens in different types of cancers.”
Zhou, Y., Wu, Y., Sun, S., Wang, W., Zhou, S., Liu, H., Guo, Y., Hong, S., Ding, F., & Cai, H. (2025) · ACS Nano · doi:10.1021/acsnano.4c15187 · Cited by 10
Cho, S., Kwak, W., Yoon, H., Lee, J., Lee, S., Park, H., Jo, S., Lee, Y., Seo, Y., Cho, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202506426 · Cited by 11
Xu, Y., Shen, H., Shang, D., & Zhu, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1665239 · Cited by 10
“Neoantigen vaccines composed of MHC class I/II-restricted neoepitopes elicited strong tumor-speci fi c immune responses and effectively induced rejection of colon cancer and melanoma xenografts in mice when delivered as poly-neoepitope mRNA formulations (230).”
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
“105 Nevertheless, not all predicted peptides are immunogenic, and accurately prioritizing immunogenic mutations remains a major challenge.”
High-content molecular profiling of T-cell therapy in oncology
Novosiadly, R. D., & Kalos, M. D. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.9 · Cited by 10
Yan, L., Li, Y., Xia, Z., Dun, Z., Chen, X., Wang, X., Liao, J., Wei, Y., & Chen, J. (2021) · Aging · doi:10.18632/aging.203771 · Cited by 11
“Thus far, several other biomarkers of potential response have been demonstrated, including high tumor mutation load [17, 18], high immunoscore [19, 20], and POLE mutation [21, 22].”
BackgroundThe dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy
Song, J., Zhang, Y., Zhou, C., Zhan, J., Cheng, X., Huang, H., Mao, S., & Zong, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112037 · Cited by 11
The Role of CD4+T Cells in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
Miao, Y., Li, Z., Feng, J., Lei, X., Shan, J., Qian, C., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136895 · Cited by 12
“Their findings were followed by a report that, in a study, immunogenic tumor neo-antigens induced a CD4 + T cell response but not the expected CD8 + T cell response [29,30].”
BackgroundWiseman, C. L., Holmes, J. P., Calfa, C. J., Dakhil, S. R., Bhattacharya, S., Peoples, G. E., Lacher, M. D., López-Lago, M. A., Kharazi, A., Priore, G. D., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2379864 · Cited by 10
Galloyl-boosted gold nanorods: Unleashing personalized cancer immunotherapy potential
Ye, J., Jiang, Y., Zhao, M., Zhang, Y., Wang, Z., Li, S., Zhang, B., Zhang, H., Zhou, T., Wang, Y., et al. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.09.100 · Cited by 10
Unveiling conserved HIV-1 open reading frames encoding T cell antigens using ribosome profiling
Bertrand, L., Nelde, A., Ramírez, B. C., Hatin, I., Arbès, H., François, P., Demais, S., Labaronne, E., Décimo, D., Guiguettaz, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56773-2 · Cited by 10
Novel Immunotherapies for the Treatment of Melanoma
Gato, M., Arasanz, H., Blanco‐Luquin, I., Glaría, E., Arteta-Sanchez, V., Kochan, G. T., & Escors, D. (2016) · Immunotherapy · doi:10.2217/imt-2015-0024 · Cited by 10
A T-cell antigen atlas for meningioma: novel options for immunotherapy
Medici, G., Freudenmann, L. K., Velz, J., Wang, S., Kapolou, K., Paramasivam, N., Mühlenbruch, L., Kowalewski, D. J., Vasella, F., Bilich, T., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02605-w · Cited by 11
“Notably, the potential of targeting HLA class II-restricted antigens was recently underscored by clinical data on the crucial role of HLA class II and CD4 + T cells in immune-mediated tumor rejection [22, 37, 43].”
BackgroundRetargeted oncolytic viruses provoke tumor-directed T-cell responses
Kloos, A., Woller, N., Gerardy‐Schahn, R., & Kühnel, F. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052933 · Cited by 10
“It is also of particular interest to investigate the involvement of neoepitope-specific CD4C T-cells which have been shown very recently to play an essential role in driving therapeutic immune responses against cancer.(9) Since polySia can be expressed by immune cells under specific conditions,(10) we also need to kno…”
BackgroundLinked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination
Savelyeva, N., Allen, A., Chotprakaikiat, W., Harden, E. L., Jobsri, J., Godeseth, R., Wang, Y., Stevenson, F. K., & Ottensmeier, C. H. H. (2016) · Current topics in microbiology and immunology · doi:10.1007/82_2016_500 · Cited by 11
Immunogenomics: using genomics to personalize cancer immunotherapy
Siniard, R. C., & Harada, S. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2140-0 · Cited by 10
“laid the foundation for this approach [43].”
BackgroundTools to define the melanoma‐associated immunopeptidome
Bräunlein, E., & Krackhardt, A. M. (2017) · Immunology · doi:10.1111/imm.12803 · Cited by 10
“The same approach was used for the identification of immunogenic MHC-II restricted neoepitopes in a murine model showing tumor rejection upon vaccination with pre-screened candidates (89).”
MethodPrzybyła, A., Lehmann, A. A., Zhang, T., Mackiewicz, J., Galus, Ł., Kirchenbaum, G. A., Mackiewicz, A. A., & Lehmann, P. (2021) · Cancers · doi:10.3390/cancers13020223 · Cited by 10
Lahman, M. C., Paulson, K. G., Nghiem, P., & Chapuis, A. G. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.12.037 · Cited by 10
“MCC can effectively dampen CD8+ T-cell recognition by decreasing class I diversity or expression, making CD4+ T-cell employment a reasonable strategy to drive immune response in tumors with limited class I (Chowell et al., 2018; Kreiter et al., 2015; Paulson et al., 2018).”
BackgroundA benchmark dataset of protein antigens for antigenicity measurement
Qiu, T., Qiu, J., Yang, Y., Zhang, L., Mao, T., Zhang, X., Xu, J., & Cao, Z. (2020) · Scientific Data · doi:10.1038/s41597-020-0555-y · Cited by 10
Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma
Lutz, J., Feist, R. K., Sonntag, T., Peguero-Sánchez, E., Wolter, K., Bick, R., Bauer, J., Walz, J. S., & Heidenreich, R. (2025) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-025-04178-x · Cited by 11
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4 + T-cell responses [36].”
Neoantigen‐Displaying Protein Nanoparticles as a Therapeutic Cancer Vaccine Against Melanoma
Kim, Y., Lee, S., Yoon, J., Shin, Y., Kang, S., Kim, S., Woo, S., Song, J., & Jon, S. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202404316 · Cited by 10
The Application of mRNA Technology for Vaccine Production—Current State of Knowledge
Paczkowska, A., Hoffmann, K., Andrzejczak, A., Pucek, W. F., Kopciuch, D., Bryl, W., Nowakowska, E., & Kus, K. (2025) · Vaccines · doi:10.3390/vaccines13040389 · Cited by 12
“Kreiter et al. used three independent murine tumor models and show that the majority of the non-synonymous tumor mutations are recognized by CD4+ T cells and vaccination with such CD4+ immunogenic mutations induce potent anti-tumor responses [55].”
InfluentialLeveraging T cells for cancer immunotherapy
Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 13
“Mouse models have confirmed the preferential induction of functional CD4 + neoantigen-specific T cells by neo-antigen vaccines [365].”
Mukherjee, A. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000120 · Cited by 10
Personalized Neo-Epitope Vaccines for Cancer Treatment
Vormehr, M., Diken, M., Türeci, Ö., Şahin, U., & Kreiter, S. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_5 · Cited by 9
Self-citationMoi, D., Zeng, B., Minnie, S. A., Bhatt, R., Wood, J., Sester, D. P., Mazzieri, R., & Dolcetti, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127896 · Cited by 9
“Tumor neo-epitopes may be also available for some preclinical cancer models (14), allowing thus a more precise assessment of the quality of tumour-specific T cell responses induced in these models by a variety of experimental immunotherapeutic strategies.”
BackgroundKou, X., He, T., Zhang, M., Wu, X., Li, X., Luo, R., Wu, R., Gou, X., Shen, M., Wu, Q., et al. (2023) · Small Methods · doi:10.1002/smtd.202300019 · Cited by 10
Yao, Y., Yan, Z., Li, C., Zhang, S., Liu, S., Zhang, X., Shi, L., Liu, W., Shi, L., & Yao, Y. (2024) · HLA · doi:10.1111/tan.15340 · Cited by 11
G protein‐coupled receptor‐mediated signaling of immunomodulation in tumor progression
Qiu, G., Yu, B., & Ma, M. (2024) · The FASEB Journal · doi:10.1096/fj.202400458r · Cited by 11
“27,28 Treg cells exert immunosuppressive effects within the TME through multiple mechanisms, such as producing immunosuppressive factors and inhibiting the function of antigen-presenting cells (APCs).”
Vaccine approaches to treat urothelial cancer
Giudice, G. C., & Sonpavde, G. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2379086 · Cited by 13
“37 To enhance their activity, several improvements have been proposed.”
BackgroundDiken, M., Vormehr, M., Grunwitz, C. R., Kreiter, S., Türeci, Ö., & Şahin, U. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_14 · Cited by 9
Self-citationPrediction of neoepitopes from murine sequencing data
Bjerregaard, A.-M., Pedersen, T. K., Marquard, A. M., & Hadrup, S. R. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2254-5 · Cited by 9
Neoantigens in tumor immunotherapy
Baryshnikova, M. A., Kosobokova, E. N., & Kosorukov, V. S. (2018) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2018-17-2-6-14 · Cited by 10
Kemps, P. G., Zondag, T. C. E., Steenwijk, E. C., Andriessen, Q., Borst, J., Vloemans, S. A., Roelen, D. L., Voortman, L. M., Verdijk, R. M., van Noesel, C. J. M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03045 · Cited by 12
Multiple Dynamics in Tumor Microenvironment Under Radiotherapy
Huang, J., & Li, J. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-44518-8_10 · Cited by 9
Yan, H.-M., Chen, Y., Wang, K., Yu, L., Huang, X., Li, Q., Xie, Y., Lin, J., He, Y., Yi, X., et al. (2020) · Aging · doi:10.18632/aging.103977 · Cited by 9
Riederer, S., Fux, R., Lehmann, M. H., Volz, A., Sutter, G., & Rojas, J. J. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.001 · Cited by 10
“Enzyme-linked immunospot (ELISPOT) assays were performed to determine the T cell response directed against the virus Molecular Therapy: Oncolytics Vol. 22 September 2021 403 (immunodominant VACV-specific B8R peptide epitope),39 a nonmutated gp100 tumor-associated antigen epitope,40 and the tumor neo-epitope B16-M30.”
ResultFraming the potential of public frameshift peptides as immunotherapy targets in colon cancer
Spaanderman, I. T., Peters, F. S., Jongejan, A., Redeker, E. J. W., Punt, C. J. A., & Bins, A. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251630 · Cited by 9
“Although new methods have recently been published [28], especially the prediction of MHC class II binding remains very challenging, whilst MHC class II presented neo-antigens seem to drive anti-tumor immunity [28,29].”
MethodMartínez‐Cortés, F., Servín-Blanco, R., Domínguez‐Romero, A. N., Munguía, M. E., Valle, J. G., Odales, J., Gevorkian, G., & Manoutcharian, K. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.08.013 · Cited by 9
Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin
Nettersheim, F. S., Picard, F. S. R., Hoyer, F. F., & Winkels, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.812702 · Cited by 10
Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy
Brentville, V. A., Symonds, P., Chua, J. X., Skinner, A., Daniels, I., Cook, K., Končarević, S., Martínez-Pinna, R., Shah, S., Choudhury, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1066185 · Cited by 9
“CD4 responses have been shown to have an increasingly important role in anticancer immunity (46, 47) and our work and that of others has shown that CD4 responses can directly mediate tumour therapy in mouse models (17, 19, 20, 37, 48).”
BackgroundOmokoko, T., Luxemburger, U., Bardissi, S., Simon, P., Utsch, M., Breitkreuz, A., Türeci, Ö., & Şahin, U. (2016) · Journal of Immunology Research · doi:10.1155/2016/9540975 · Cited by 9
“Cancer immunotherapy is emerging as an important contributor to the armamentarium of future oncology treatments [1– 4].”
Self-citationIn Silico Typing of Classical and Non-classical HLA Alleles from Standard RNA-Seq Reads
Boegel, S., Bukur, T., Castle, J. C., & Şahin, U. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8546-3_12 · Cited by 9
Self-citationHayashi, S., Moriyama, T., Yamaguchi, R., Mizuno, S., Komura, M., Miyano, S., Nakagawa, H., & Imoto, S. (2019) · Journal of Computational Biology · doi:10.1089/cmb.2018.0224 · Cited by 9
“Recently, the interaction between cancer and the immune system has attracted attention (Grivennikov et al., 2010; Schreiber et al., 2011; Kreiter et al., 2015; Rooney et al., 2015; Marty et al., 2017), and somatic mutations in HLA genes have been shown to accumulate in specific cancer types (The Cancer Genome Atlas Re…”
BackgroundDeciphering the landscape of phosphorylated HLA-II ligands
Solleder, M., Racle, J., Guillaume, P., Coukos, G., Bassani-Sternberg, M., & Gfeller, D. (2022) · iScience · doi:10.1016/j.isci.2022.104215 · Cited by 9
Shen, W., Hu, D., Gong, C., Cheng, F., Luo, J., Wang, L., Yao, C., Wu, H., Zhao, C., & Zhu, S. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01134-w · Cited by 8
“For CD4 + T cells, some studies have reported a role for neoantigen-specific CD4 + T-cell responses in direct tumor clearance [57–59], and CD4 + T cells can exert direct antitumor effects independent of CD8 + T cells [60, 61].”
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
Gomar, C., Trani, C. A. D., Bella, Á., Arrizabalaga, L., González-Gomariz, J., Fernández-Sendin, M., Álvarez, M., Russo-Cabrera, J. S., Ardaiz, N., Aranda, F., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008287 · Cited by 8
Meng, W., Takeuchi, Y., Ward, J. P., Sultan, H., Arthur, C. D., Mardis, E. R., Artyomov, M. N., Lichti, C. F., & Schreiber, R. D. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0900 · Cited by 8
Sharif, E., Nezafat, N., Ahmadi, F. M., & Mohit, E. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-04971-x · Cited by 8
“Previously, it was reported that vaccination with polytope mRNA vaccines containing CT26-M19 as MHC class I, and CT26-M68 as MHC class I-restricted mutation can induce strong antitumor activity [22].”
InfluentialMatsumoto, S., Tsujikawa, T., Tokita, S., Bedeir, M. M., Matsuo, K., Hata, F., Hirohashi, Y., Kanaseki, T., & Torigoe, T. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2404665 · Cited by 9
“4 In a clinical setting, a patient with cholangiocarcinoma experienced tumor regression following adoptive transfer of neoantigen-recognizing Th1-like cells.”
Sharif, E., Nezafat, N., & Mohit, E. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113283 · Cited by 8
Novakova, A., Morris, S. A., Vaiarelli, L., & Frank, S. (2025) · Vaccines · doi:10.3390/vaccines13020144 · Cited by 9
“…neoantigen-speci fi c T-cells are generated against neoantigens not contained within the vaccine [ This approach shows promise in addressing the poor prognosis associated with high tumour heterogeneity in TNBC, as the expanded immune landscape may facilitate overcoming this challenge [59].”
Dietrich, K. A., & Theobald, M. (2015) · Der Internist · doi:10.1007/s00108-015-3744-6 · Cited by 8
Position‐Scanning Peptide Libraries as Particle Immunogens for Improving CD8+ T‐Cell Responses
He, X., Zhou, S., Quinn, B., Huang, W., Jahagirdar, D., Vega, M., Ortega, J., Long, M. D., Ito, F., Abrams, S. I., et al. (2021) · Advanced Science · doi:10.1002/advs.202103023 · Cited by 8
Metadata
- Authors
- Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Nature
- Published
- 2015-04-22
- Volume
- 520
- Issue
- 7549
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4838069
- OpenAlex
- W2079696222
- Cited by
- 1,243
- References
- 31
- Citations by year
- 2026: 64 · 2025: 93 · 2024: 114 · 2023: 120 · 2022: 124 · 2021: 149 · 2020: 144 · 2019: 101 · 2018: 99 · 2017: 99 · 2016: 95 · 2015: 38
- FWCI
- 54.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-06-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI107010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- tumour mutations, MHC class II epitopes, neoantigens, CD4+ T cells, mRNA vaccines, personalized cancer immunotherapy, MHC class II binding prediction, tumor microenvironment, cytotoxic T lymphocytes, tumor rejection, exome sequencing, tumor immunogenicity
- MeSH terms
- Algorithms, Animals, Histocompatibility Antigens Class II, Computer Simulation, Disease Models, Animal, Female, Humans, Immunotherapy, Melanoma, Experimental, Mutation, CD4-Positive T-Lymphocytes, Survival Analysis, Sequence Analysis, DNA, Epitopes, T-Lymphocyte, Cancer Vaccines, Mice, Precision Medicine, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.